Executive Summary
Choline Alfoscerate (α-GPC) is a highly bioavailable choline source with proven relevance in cognitive health and neuroprotection. As a precursor to acetylcholine and phosphatidylcholine, it directly addresses age-related cholinergic decline, a key driver of cognitive impairment and neurodegeneration.
Clinical evidence supports α-GPC across Alzheimer’s disease, vascular dementia, stroke recovery, traumatic brain injury, and mild cognitive impairment. Its mechanisms include enhanced cholinergic signaling, membrane phospholipid support, reduced neuroinflammation, and activation of neurotrophic pathways such as BDNF.
With GRAS status, a strong safety profile, and broad regulatory acceptance, α-GPC is well positioned as a scalable, clinically validated solution for cognitive aging and brain health.
Introduction
Global population aging is driving a rapid increase in neurodegenerative and age-related cognitive disorders, placing growing clinical and socioeconomic strain on healthcare systems. Targeting cholinergic dysfunction is central to delaying cognitive decline.
Choline Alfoscerate (α-GPC) is a naturally occurring, highly bioavailable precursor of acetylcholine and phosphatidylcholine that readily crosses the blood–brain barrier. It enhances cholinergic neurotransmission, supports synaptic plasticity and membrane repair, and modulates neuroinflammatory and neurogenic pathways.
With a strong safety profile and GRAS status, α-GPC is increasingly adopted in pharmaceutical and nutraceutical formulations as a clinically validated intervention for cognitive aging.
Chemistry
| Structure | |
| Synonyms | Choline Alfoscerate, α-GPC, sn-glycero-3-phosphocholine, Choline glycerophosphate, Glycerophosphocholine |
| IUPAC Name | [(2R)-2,3-dihydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate |
| Molecular Formula | C8H20NO6P |
| Molecular Weight | 257.22 g/mol |
Mechanism of Action
Alpha-GPC serves as a precursor to acetylcholine & phosphatidylcholine. Its key actions include:
- Enhancing acetylcholine levels in the brain, facilitating memory and cognitive processes.
- Supporting membrane phospholipid synthesis, thereby aiding neuronal repair and structural integrity.
- Modulating dopaminergic and serotonergic pathways, which helps reduce apathy and mood symptoms.
- Increasing neurotrophic factors like BDNF and promoting hippocampal neurogenesis.
- Protecting neurons from glutamate toxicity via nicotinic acetylcholine receptor activation.
Representative Clinical Findings
| Indication | Clinical Outcome | Representative Evidence |
| Cognitive Decline & Dementia | Improves cognitive performance, behavior, and functional outcomes in Alzheimer’s and vascular dementia | Multicenter RCT (n=261): α-GPC 400 mg TID for 180 days significantly improved MMSE, ADAS-Cog, and behavioral scores[1] |
| Post-Stroke Recovery | Enhances neuroplasticity, cognitive recovery, and reduces post-stroke depressive symptoms | Meta-analyses and controlled clinical studies demonstrate improved functional and cognitive recovery following ischemic stroke[2] |
| Mild Cognitive Impairment (MCI) | Improves attention and language; delays progression toward dementia | RCTs (n≈100): α-GPC 600 mg/day significantly improved ADAS-Cog and language domains[3],[4] |
| Depression in the Elderly | Reduces apathy and mood symptoms, particularly as adjunct therapy | Narrative and clinical reviews report synergistic effects with cholinesterase inhibitors (e.g., donepezil)[5] |
| Traumatic Brain Injury (TBI) | Supports cognitive recovery and improves global cognitive scores | Prospective study: 8-week α-GPC administration improved MMSE and post-traumatic cognitive symptoms[6] |
| Age-Related Hearing Loss | Enhances central auditory processing and speech discrimination | 11-month clinical study demonstrated significant improvement in word recognition scores and neuroprotection of central auditory pathways[7] |
| Neurodegenerative Disorders | Supports neuronal structure and may slow functional decline | Preclinical models and early human studies indicate cholinergic and neuroprotective effects[8],[9] |
| Athletic & Cognitive Performance | Enhances focus and neuromuscular performance; transient growth hormone release | Human studies demonstrate cholinergic-mediated pituitary stimulation and nootropic effects in healthy adults[10] |
Typical Dosage Forms
| Formulation Type | Administration & Dose | Typical Use / Notes |
| Capsule / Tablet | Oral; 400–1200 mg/day for 2–6 months | Cognitive support in dementia and age-related cognitive decline |
| Injectable Ampoule | IM or IV; 1000 mg/day for 5–10 days (up to ~30 days in select cases) | Acute neurological recovery following stroke or traumatic brain injury |
| Syrup (Liquid) | Oral; 300–600 mg/day (up to 1200 mg/day) for ≤6 months | Suitable for patients with swallowing difficulties; bioequivalent to capsules |
| Powder (50–99% purity) | Oral supplement; 250–1200 mg/day; medium- to long-term use | Supports acetylcholine synthesis, cognitive performance, and physical performance |
Examples of Marketed Finished Products
| Brand | Region | Indication | Photo |
| Gliatilin | IT | Vascular dementia, Alzheimer’s, cognitive decline | |
| Noocolina | RO | Vascular neurocognitive disorders | |
| Alfocetine | KR | Brain Function Improvement | |
| NOW Foods Alpha-GPC | US | Supplement for Brain support, cognitive clarity | |
| Centrolin | UA | Acute severe craniocerebral injury with impaired consciousness | |
| Cerotiline | BY | Senile cognitive affective decline | |
| Cerepro | RU | Cerebrovascular insufficiency |
Representative Customers using VAV’s Choline Alfoscerate
| Region | Customer Profile / Market Segment | Finished Dosage Forms |
| Eastern Europe | Multinational pharmaceutical CDMO focused on neuro-specialty drug manufacturing | Injectable solutions (ampoules), oral solutions, soft-gel capsules |
| Central & Eastern Europe | Hospital-affiliated clinical-trial CDMO | Injectable solutions (ampoules) |
| Middle East & Central Asia | Pharmaceutical CDMO developing therapies for cognitive disorders | Injectable solutions (ampoules) |
| CIS | Neuro-focused pharmaceutical CDMO specializing in cognitive and post-stroke therapies | Capsules, injectable solutions |
| South Asia | Pharmaceutical CDMO supplying hospital-based formulations | Non-branded / institutional supply |
| Western Europe | Neuro-specialty CDMO developing cognitive-disorder therapies | Injectable solutions (ampoules), soft-gel capsules |
Conclusion
Choline Alfoscerate (α-GPC) is a highly bioavailable cholinergic precursor with proven central nervous system penetration and a defined role in acetylcholine synthesis and membrane phospholipid metabolism. By addressing cholinergic dysfunction and impaired membrane turnover, α-GPC targets core mechanisms underlying age-related cognitive decline and neurodegeneration.
Clinical evidence demonstrates efficacy in Alzheimer’s disease, vascular dementia, mild cognitive impairment, and post-ischemic and traumatic brain injury, with consistent improvements in cognitive and functional outcomes and a favorable safety profile. Preclinical findings further support its role in modulating neuroinflammation, neurotrophic signaling, and synaptic plasticity.
With established regulatory acceptance and broad formulation compatibility, α-GPC represents a scientifically validated approach to cognitive support and neuroprotection, meriting continued investigation into its long-term and disease-modifying potential.
References
- Moreno Moreno MJ. Cognitive improvement in mild–moderate Alzheimer’s disease with choline alfoscerate: multicenter double-blind RCT. Clin Ther. 2003;25:178–193.
- Sagaro GG, Amenta F. Choline-containing phospholipids in stroke treatment: systematic review and meta-analysis. J Clin Med. 2023;12:2875.
- Kim HK et al. L-α-glycerylphosphorylcholine use associated with delayed dementia conversion: nationwide longitudinal study. J Prev Alzheimer’s Dis. 2025;12:100059.
- Jeon J et al. Efficacy and safety of choline alfoscerate in amnestic mild cognitive impairment: randomized double-blind placebo-controlled trial. BMC Geriatr. 2024;24:774.
- Granata N et al. Choline alfoscerate for management of subthreshold depression in older adults. Geriatrics. 2025;10:32.
- Park MS et al. Choline alfoscerate improves cognitive dysfunction after mild traumatic brain injury: prospective case-control study. Korean J Neurotrauma. 2025;21:114–123.
- Na G et al. Choline alfoscerate supplementation improves speech recognition in age-related hearing loss. Front Aging Neurosci. 2021;13:684519.
- Catanesi M et al. Neuroprotective effects of choline alfoscerate against β-amyloid toxicity via neurotrophic signaling. Cell Biol Int. 2020;44:1734–1744.
- Lee SH et al. Choline alfoscerate enhances hippocampal neurogenesis and protects against seizure-induced cognitive impairment. Brain Res. 2017;1654:66–76.
- Kerksick CM. Acute α-GPC supplementation enhances cognitive performance in healthy men. Nutrients. 2024;16:4240.